These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32405876)

  • 21. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Diabetes Ther; 2020 Nov; 11(11):2657-2676. PubMed ID: 32930969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Diabetic Kidney Disease: Current and Future.
    Yamazaki T; Mimura I; Tanaka T; Nangaku M
    Diabetes Metab J; 2021 Jan; 45(1):11-26. PubMed ID: 33508907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
    Lam D; Nadkarni GN; Mosoyan G; Neal B; Mahaffey KW; Rosenthal N; Hansen MK; Heerspink HJL; Fleming F; Coca SG
    Am J Nephrol; 2022; 53(1):21-31. PubMed ID: 35016188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CREDENCE: Significant Victory for Diabetic Kidney Disease.
    Verma A; Patel AB; Upadhyay A; Waikar SS
    Trends Endocrinol Metab; 2020 Jun; 31(6):391-393. PubMed ID: 32327275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m
    Bakris G; Oshima M; Mahaffey KW; Agarwal R; Cannon CP; Capuano G; Charytan DM; de Zeeuw D; Edwards R; Greene T; Heerspink HJL; Levin A; Neal B; Oh R; Pollock C; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Jardine MJ; Perkovic V
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1705-1714. PubMed ID: 33214158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
    Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A
    Diabetes Obes Metab; 2023 Aug; 25(8):2331-2339. PubMed ID: 37184050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Canagliflozin: metabolic, cardiovascular and renal protection.
    Barrios V; Escobar C
    Future Cardiol; 2021 May; 17(3):443-458. PubMed ID: 33538620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials.
    Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL
    J Am Heart Assoc; 2023 Jul; 12(13):e028516. PubMed ID: 37345834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
    Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
    Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials.
    Gohda T; Murakoshi M
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
    Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
    Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
    Charytan DM; Mahaffey KW; Jardine MJ; Cannon CP; Neal B; Lambers Heerspink HJ; Agarwal R; Bakris GL; de Zeeuw D; Levin A; Pollock C; Zhang H; Zinman B; Rosenthal N; Perkovic V; Di Tanna GL; Yu J; Rogers K; Arnott C; Wheeler DC
    BMJ Open Diabetes Res Care; 2023 Jun; 11(3):. PubMed ID: 37311602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.
    Liu AYL; Low S; Yeoh E; Lim EK; Renaud CJ; Teoh STY; Tan GFL; Chai CC; Liu B; Subramaniam T; Sum CF; Lim SC
    Clin Kidney J; 2022 Jul; 15(7):1403-1414. PubMed ID: 35756732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
    Wish JB; Pergola P
    Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.